- Home
- TCRX vs IMUX Comparison
TCRX vs IMUX Comparison
Compare TCRX & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- IMUX
- Stock Information
- Founded
- TCRX 2018
- IMUX 2016
- Country
- TCRX United States
- IMUX United States
- Employees
- TCRX N/A
- IMUX N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- TCRX Health Care
- IMUX Health Care
- Exchange
- TCRX Nasdaq
- IMUX Nasdaq
- Market Cap
- TCRX 91.7M
- IMUX 90.4M
- IPO Year
- TCRX 2021
- IMUX N/A
- Fundamental
- Price
- TCRX $1.60
- IMUX $0.83
- Analyst Decision
- TCRX Strong Buy
- IMUX Strong Buy
- Analyst Count
- TCRX 5
- IMUX 5
- Target Price
- TCRX $9.40
- IMUX $7.50
- AVG Volume (30 Days)
- TCRX 219.1K
- IMUX 1.3M
- Earning Date
- TCRX 11-11-2025
- IMUX 11-06-2025
- Dividend Yield
- TCRX N/A
- IMUX N/A
- EPS Growth
- TCRX N/A
- IMUX N/A
- EPS
- TCRX N/A
- IMUX N/A
- Revenue
- TCRX $6,961,000.00
- IMUX N/A
- Revenue This Year
- TCRX $255.18
- IMUX N/A
- Revenue Next Year
- TCRX N/A
- IMUX N/A
- P/E Ratio
- TCRX N/A
- IMUX N/A
- Revenue Growth
- TCRX N/A
- IMUX N/A
- 52 Week Low
- TCRX $1.02
- IMUX $0.56
- 52 Week High
- TCRX $6.23
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- TCRX 36.40
- IMUX 47.55
- Support Level
- TCRX $1.73
- IMUX $0.75
- Resistance Level
- TCRX $1.96
- IMUX $0.90
- Average True Range (ATR)
- TCRX 0.11
- IMUX 0.06
- MACD
- TCRX -0.03
- IMUX 0.00
- Stochastic Oscillator
- TCRX 0.00
- IMUX 56.34
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.